Skip to main content
Clinical Trials/NCT03375008
NCT03375008
Completed
Not Applicable

Development of Non-invasive Magnetic Resonance Imaging Diagnostic Method for Nonalcoholic Steatohepatitis(NASH)

Korea University Guro Hospital1 site in 1 country47 target enrollmentSeptember 8, 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Nonalcoholic Steatohepatitis
Sponsor
Korea University Guro Hospital
Enrollment
47
Locations
1
Primary Endpoint
Radiologic Diagnosis & Criteria of nonalcoholic steatohepatitis(NASH)
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

  1. To evaluate feasibility of using multiparametric Magnetic resonance(MR) imaging to predict nonalcoholic steatohepatitis(NASH)
  2. To develop non-invasive diagnosis tool using multiparametric Magnetic resonance(MR) imaging for nonalcoholic steatohepatitis(NASH)

Detailed Description

Nonalcoholic steatohepatitis(NASH) is a severe form of nonalcoholic fatty liver disease(NAFLD). The causes are known to be associated with metabolic diseases such as obesity, insulin resistance type 2 diabetes, and hypercholesterolemia. Histologically, it is characterized by steatosis, hepatocellular injury, and inflammation and fibrosis of the liver parenchyma. Nonalcoholic steatohepatitis (NASH) may progress to cirrhosis and hepatocellular carcinoma(HCC) may develop even in patients without viral hepatitis, therefore there have been much interest and many researches in causation and diagnosis for nonalcoholic steatohepatitis(NASH). Liver biopsy remains the gold standard for the diagnosis of nonalcoholic fatty liver disease(NAFLD) and is the only reliable method for differentiating nonalcoholic steatohepatitis(NASH) from simple steatosis. However, liver biopsy has several drawbacks, including invasiveness, potential complications such as excessive bleeding and death, sampling error, and inter- and intra-observer variability. Magnetic resonance(MR) imaging has been used as a multiparametric imaging tool with which to evaluate steatosis by chemical shift imaging andm magnetic resonance(MR) spectroscopy, and fibrosis by magnetic resonance(MR) elastography and T1 mapping. To the best of our knowledge, there is no accurate imaging diagnostic tool for nonalcoholic steatohepatitis(NASH), therefore the investigators aimed to develop non-invasive imaging diagnostic model using multiparametric magnetic resonance imager(MRI).

Registry
clinicaltrials.gov
Start Date
September 8, 2016
End Date
August 7, 2018
Last Updated
6 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Chang Hee Lee

Professor

Korea University Guro Hospital

Eligibility Criteria

Inclusion Criteria

  • Patients \>19 years age
  • Patients who had elevated aspartate transaminase(AST)/alanine transaminase(ALT) and fatty liver on abdominal ultrasonography
  • Patients who are clinically suspected to have nonalcoholic steatohepatitis(NASH)
  • Clinically suspected nonalcoholic steatohepatitis(NASH): \>40 years age, metabolic syndrome, fibrosis on transient elastography(TE, Fibroscan), or elevated Fibrosis-4(FIB-4), Aspartate aminotransferase-to-platelet ratio index(APRI), nonalcoholic fatty liver disease fibrosis score(NFS) on blood tests
  • Patients who underwent (\<6 months) or will undergo US-guided liver biopsy

Exclusion Criteria

  • Chronic liver disease other than nonalcoholic fatty liver disease(NAFLD) (chronic hepatitis B or C, autoimmune hepatitis, primary biliary sclerosis)
  • Alcohol abuse (men, \>140g/week; women, \>70g/week)
  • Fatty liver due to medication
  • Contraindication to magnetic resonance imager(MRI)
  • Hepatocellular carcinoma

Outcomes

Primary Outcomes

Radiologic Diagnosis & Criteria of nonalcoholic steatohepatitis(NASH)

Time Frame: up to 23 month

Development of non-invasive magnetic resonance imaging diagnostic model for NASH using linear regression analysis 1. Linear regression analysis using three magnetic resonance(MR) parameters 1) Fat signal fraction measured on MR spectroscopy (unit: %) 2) Liver stiffness measured on MR elastography (unit: kPa) 3) T1 relaxation time measured on T1 mapping (unit: msec) → Development of linear equation for NAFLD activity score (NAS) and Steatosis, Activity, Fibrosis (SAF) score 2. Fitting of observed values (NAS, SAF score) and predicted values (NAS, SAF score) → Obtaining R square (R2) (Unit: none)

Secondary Outcomes

  • Histologic interpretation(1) : Steatosis, Activity, Fibrosis (SAF) score(Up to a week)
  • Fibrosis imaging(1) : Liver stiffness measured on magnetic resonance elastography(MRE)(During scanning, up to 20 seconds)
  • Fat imaging : Fat signal fraction measured on magnetic resonance(MR) spectroscopy(During scanning, up to 15 seconds)
  • Fibrosis imaging(2) : T1 relaxation time measured on T1 mapping(During scanning, up to 20 seconds)
  • Histologic interpretation(1) : Nonalcoholic fatty liver disease activity score (NAS)(Up to a week)

Study Sites (1)

Loading locations...

Similar Trials